logo-loader
viewCircassia Pharmaceuticals PLC

Circassia Pharmaceuticals adds 'exciting, near-term' respiratory drug to portfolio

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), tells Proactive London's Andrew Scott they've acquired the exclusive US and Chinese commercialisation rights to AirNOvent – a treatment for persistent pulmonary hypertension (PPHN) of newborns.

PPHN occurs when the pressure in the blood vessels of a baby’s lungs remains high after birth, which can restrict the amount of oxygen flowing around the body and make the newborn unwell.

It's thought to occur in around one in 500 births.

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.74 GBX

LSE:CIR
Market: LSE
Market Cap: £66.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read